Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Cash from Financing Activities of $2.9 million for Q1 2026, down 97.33% quarter-over-quarter from $108.6 million in Q4 2025.
Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Cash from Financing Activities for 7 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $111.4 million (up 8.0% YoY), while the FY2025 annual figure was $108.5 million, up 4.82% from the prior year.
- Cash from Financing Activities eased to $2.9 million in Q1 2026 per IKT's latest filing, from $108.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $108.6 million in Q4 2025 and bottomed at -$204769.0 in Q1 2022.
- Historically, Cash from Financing Activities has averaged $17.2 million across 5 years, with a median of $181954.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 259834.29% — and 2025, when it slumped 173.72%.
- Inhibikase Therapeutics' Cash from Financing Activities stood at -$204769.0 in 2022, then surged by 32.56% to -$138104.0 in 2023, then soared by 72280.72% to $99.7 million in 2024, then gained by 8.91% to $108.6 million in 2025, then tumbled by 97.33% to $2.9 million in 2026.
- Business Quant data shows IKT's Cash from Financing Activities at $2.9 million in Q1 2026, $108.6 million in Q4 2025, and -$134130.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -14,489.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14,489.00 |
| Jun 30, 2026 | -14,489.00 |
| Mar 31, 2026 | 2.90 Mn |
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 108.57 Mn |
| Dec 31, 2025 | 108.57 Mn |
| Sep 30, 2025 | -134,130.00 |
| Sep 30, 2025 | -134,130.00 |
| Jun 30, 2025 | 31,771.00 |
| Jun 30, 2025 | 31,771.00 |
| Dec 31, 2024 | 99.68 Mn |
| Dec 31, 2024 | 99.68 Mn |
| Sep 30, 2024 | 181,954.00 |
| Sep 30, 2024 | 181,954.00 |
| Jun 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 366,999.00 |
| Mar 31, 2024 | 366,999.00 |
| Dec 31, 2023 | -138,104.00 |
| Dec 31, 2023 | -138,104.00 |